Epidermal growth factor receptor targeting in cancer: A review of trends and strategies

Efflux by Small Multidrug Resistance Proteins Is Inhibited by Membrane-interactive Helix-stapled Peptides

“…Such functionality may be of considerable utility in situations beyond the present instance of efflux pump expressing multidrug-resistant bacteria, to multidrug-resistant cancer cells that use efflux pumps of the ABC binding cassette for transport of chemotherapeutics (34), or to oncogenic G-protein coupled receptors that constitutively signal upon dimerization (e.g. epidermal growth factor receptor) (35). Our work therefore represents not only an important step in the development of peptide therapeutics against diseases caused by tertiary or quaternary helix-helix interactions in membrane proteins, but portends the validity of similar approaches to the disruption of protein-protein interactions in membranes.…”

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

“…We hypothesized that highly proliferative tumors, assessed by the surrogate marker of Ki-67 protein expression, would respond more robustly to induction chemotherapy agents that were selectively more toxic to cycling cells, including microtubule inhibitors, antimetabolites, and an EGFR inhibitor [27,28]. In multivariate regression analysis, we did not find a significant relationship between pretreatment Ki-67 protein expression level and tumor response to the induction chemotherapy regimens of APF-C and TPF+/-C as assessed by visual examination of the primary site, anatomic change based on CT scan, or metabolic change based on FDG-PET/CT.…”

“…In this retrospective analysis, we assessed Ki-67 protein expression level as a predictive biomarker of tumor response to two cycles of induction chemotherapy with nab-paclitaxel or docetaxel, each given with cisplatin, 5-FU, +/− cetuximab in patients with locally advanced HNSCC. Based on the strong association between high Ki-67 expression and cell proliferation, we hypothesized that tumors with higher versus lower Ki-67 expression would respond more robustly to induction chemotherapy regimens containing agents that were selectively toxic to cycling cells, including microtubule inhibitors (nab-paclitaxel or docetaxel), antimetabolites (5-FU), and an EGFR inhibitor (cetuximab) [27,28].…”

Prognostic significance and therapeutic implications of PTEN, EGFR and MAPK/ERK in cervical squamous cell carcinoma

“…Therefore, there is a considerable need for cervical cancer treatments. The epidermal growth factor receptor (EGFR) is a well characterized target for anti-cancer therapies in many tumors [5]. Its stimulation activates a tyrosine kinase domain that affects multiple cellular functions including growth and replication [6].…”

“…EGFR pathway could be inhibited pharmacologically through two ways: anti-EGFR monoclonal antibodies or specific inhibitors of the EGFR tyrosine kinase domain. Clinical significance of anti-EGFR therapies were detected in lung, colon, and other tumors [5].…”